Linda Hwee-Lin Lua
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Linda Hwee-Lin Lua has a total of 217 co-authors. Here are the top co-authors by number of shared publications:
Yap P. Chuan
Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, Brisbane, QLD, Australia
15 shared publications- Anton Peter Jacob Middelberg
Division of Research and Innovation The University of Adelaide Adelaide South Australia Australia
14 shared publications Anton P.J. Middelberg
The University of Queensland, Australian Institute for Bioengineering and Nanotechnology, St Lucia, QLD 4072, Australia
13 shared publicationsNani Wibowo
The University of Queensland, Australian Institute for Bioengineering and Nanotechnology, St Lucia, QLD 4072, Australia
13 shared publications- Natalie K. Connors
The University of Queensland, Australian Institute for Bioengineering and Nanotechnology, Centre for Biomolecular Engineering, St Lucia, Queensland 4072, Australia
11 shared publications Yang Wu
The University of Queensland, Australian Institute for Bioengineering and Nanotechnology, St Lucia, QLD 4072, Australia
7 shared publications
Latest Publications
- 31 August 2024
- Published by Elsevier in Chemico-Biological Interactions
- Vol. 403, 111219
Effective parallel evaluation of molecular design, expression and bioactivity of novel recombinant butyrylcholinesterase medical countermeasures
- 31 August 2024
- Published by Elsevier in Chemico-Biological Interactions
- Vol. 403, 111219
Effective parallel evaluation of molecular design, expression and bioactivity of novel recombinant butyrylcholinesterase medical countermeasures
- 6 September 2022
- Published by Springer Nature
- p. 143-157
Bioproduction of Cyclic Disulfide-Rich Peptides for Drug Modalities
- 6 September 2022
- Published by Springer Nature
- p. 143-157
Bioproduction of Cyclic Disulfide-Rich Peptides for Drug Modalities
- 1 January 2022
- Published by Springer Nature
- Vol. 2406, 93-111
Protein Expression Optimization Strategies in E. coli: A Tailored Approach in Strain Selection and Parallelizing Expression Conditions
Escherichia coli remains a traditional and widely used host organism for recombinant protein production. Its well-studied genome, availability of vectors and strains, cheap and relatively straight-forward cultivation methods paired with reported high protein yields are reasons why E. coli is often the first-choice host expression system for recombinant protein production. The chapter enclosed here details protocols and design strategies in strain selection and methods on how to parallelize expression conditions to optimize for soluble target protein expression in E. coli. The methods described have been validated in a protein production research facility.
- 1 January 2022
- Published by Springer Nature
- Vol. 2406, 93-111
Protein Expression Optimization Strategies in E. coli: A Tailored Approach in Strain Selection and Parallelizing Expression Conditions
Escherichia coli remains a traditional and widely used host organism for recombinant protein production. Its well-studied genome, availability of vectors and strains, cheap and relatively straight-forward cultivation methods paired with reported high protein yields are reasons why E. coli is often the first-choice host expression system for recombinant protein production. The chapter enclosed here details protocols and design strategies in strain selection and methods on how to parallelize expression conditions to optimize for soluble target protein expression in E. coli. The methods described have been validated in a protein production research facility.
- 17 February 2021
- Published by Springer Nature in Nature Protocols
- Vol. 16 (3) , 1740-1760
Yeast-based bioproduction of disulfide-rich peptides and their cyclization via asparaginyl endopeptidases
Cyclic disulfide-rich peptides have attracted significant interest in drug development and biotechnology. Here, we describe a protocol for producing cyclic peptide precursors in Pichia pastoris that undergo in vitro enzymatic maturation into cyclic peptides using recombinant asparaginyl endopeptidases (AEPs). Peptide precursors are expressed with a C-terminal His tag and secreted into the media, enabling facile purification by immobilized metal affinity chromatography. After AEP-mediated cyclization, cyclic peptides are purified by reverse-phase high-performance liquid chromatography and characterized by mass spectrometry, peptide mass fingerprinting, NMR spectroscopy, and activity assays. We demonstrate the broad applicability of this protocol by generating cyclic peptides from three distinct classes that are either naturally occurring or synthetically backbone cyclized, and range in size from 14 amino acids with one disulfide bond, to 34 amino acids with a cystine knot comprising three disulfide bonds. The protocol requires 14 d to identify and optimize a high-expressing Pichia clone in small-scale cultures (24 well plates or 50 mL tubes), after which large-scale production in a bioreactor and peptide purification can be completed in 10 d. We use the cyclotide Momordica cochinchinensis trypsin inhibitor II as an example. We also include a protocol for recombinant AEP production in Escherichia coli as AEPs are emerging tools for orthogonal peptide and protein ligation. We focus on two AEPs that preferentially cyclize different peptide precursors, namely an engineered AEP with improved catalytic efficiency [C247A]OaAEP1b and the plant-derived MCoAEP2. Rudimentary proficiency and equipment in molecular biology, protein biochemistry and analytical chemistry are needed.
- 17 February 2021
- Published by Springer Nature in Nature Protocols
- Vol. 16 (3) , 1740-1760
Yeast-based bioproduction of disulfide-rich peptides and their cyclization via asparaginyl endopeptidases
Cyclic disulfide-rich peptides have attracted significant interest in drug development and biotechnology. Here, we describe a protocol for producing cyclic peptide precursors in Pichia pastoris that undergo in vitro enzymatic maturation into cyclic peptides using recombinant asparaginyl endopeptidases (AEPs). Peptide precursors are expressed with a C-terminal His tag and secreted into the media, enabling facile purification by immobilized metal affinity chromatography. After AEP-mediated cyclization, cyclic peptides are purified by reverse-phase high-performance liquid chromatography and characterized by mass spectrometry, peptide mass fingerprinting, NMR spectroscopy, and activity assays. We demonstrate the broad applicability of this protocol by generating cyclic peptides from three distinct classes that are either naturally occurring or synthetically backbone cyclized, and range in size from 14 amino acids with one disulfide bond, to 34 amino acids with a cystine knot comprising three disulfide bonds. The protocol requires 14 d to identify and optimize a high-expressing Pichia clone in small-scale cultures (24 well plates or 50 mL tubes), after which large-scale production in a bioreactor and peptide purification can be completed in 10 d. We use the cyclotide Momordica cochinchinensis trypsin inhibitor II as an example. We also include a protocol for recombinant AEP production in Escherichia coli as AEPs are emerging tools for orthogonal peptide and protein ligation. We focus on two AEPs that preferentially cyclize different peptide precursors, namely an engineered AEP with improved catalytic efficiency [C247A]OaAEP1b and the plant-derived MCoAEP2. Rudimentary proficiency and equipment in molecular biology, protein biochemistry and analytical chemistry are needed.
- Open Access
- 1 October 2020
- Published by Wiley in Biotechnology Journal
- Vol. 16 (3) , e2000309
Intensified Downstream Processing of Monoclonal Antibodies Using Membrane Technology
The need to intensify downstream processing of monoclonal antibodies to complement the advances in upstream productivity has led to increased attention toward implementing membrane technologies. With the industry moving toward continuous operations and single use processes, membrane technologies show promise in fulfilling the industry needs due to their operational flexibility and ease of implementation. Recently, the applicability of membrane‐based unit operations in integrating the downstream process has been explored. In this article, the major developments in the application of membrane‐based technologies in the bioprocessing of monoclonal antibodies are reviewed. The recent progress toward developing intensified end‐to‐end bioprocesses and the critical role membrane technology will play in achieving this goal are focused upon.
- 1 October 2020
- Published by Wiley in Biotechnology Journal
- Vol. 16 (3) , e2000309
Open AccessIntensified Downstream Processing of Monoclonal Antibodies Using Membrane Technology
The need to intensify downstream processing of monoclonal antibodies to complement the advances in upstream productivity has led to increased attention toward implementing membrane technologies. With the industry moving toward continuous operations and single use processes, membrane technologies show promise in fulfilling the industry needs due to their operational flexibility and ease of implementation. Recently, the applicability of membrane‐based unit operations in integrating the downstream process has been explored. In this article, the major developments in the application of membrane‐based technologies in the bioprocessing of monoclonal antibodies are reviewed. The recent progress toward developing intensified end‐to‐end bioprocesses and the critical role membrane technology will play in achieving this goal are focused upon.
- 1 July 2020
- Published by Royal Society of Chemistry (RSC) in Green Chemistry
- Vol. 22 (15) , 5002-5016
An environmentally sustainable biomimetic production of cyclic disulfide-rich peptides
Macrocyclic, disulfide-rich peptides have found widespread applications in drug design and development. Current peptide production strategies rely heavily on solid phase peptide synthesis (SPPS) requiring large amounts of hazardous/toxic reagents and solvents which have negative environmental impacts. A possible solution is to develop a sustainable hybrid production platform incorporating recombinant production of cyclic peptide precursors in yeast followed by enzymatic maturation of these precursors into cyclic peptides using asparaginyl endopeptidases in vitro. Harnessing the efficient secretory pathway of Pichia pastoris, peptide precursors, cloned downstream of the α-mating factor secretion signal, were purified from culture supernatant mitigating the need for complex purification. To demonstrate the broad utility of the platform, three distinct classes of cyclic peptides were produced; two were structurally validated by NMR and shown to be functionally equivalent to their synthetically produced versions. Furthermore, using this platform we report the first recombinant production of any α-conotoxin in its native “globular” conformation. Using scale-up production in bioreactors, cyclic peptide yields of 85–97 mg L−1 of culture were achieved, far exceeding the highest yields so far achieved for cyclic disulfide-rich peptides in any recombinant process. This platform can potentially unlock production and facilitate applications of cyclic disulfide-rich peptides previously inaccessible through large-scale chemical synthesis and reduce their environmental burden.
- 1 July 2020
- Published by Royal Society of Chemistry (RSC) in Green Chemistry
- Vol. 22 (15) , 5002-5016
An environmentally sustainable biomimetic production of cyclic disulfide-rich peptides
Macrocyclic, disulfide-rich peptides have found widespread applications in drug design and development. Current peptide production strategies rely heavily on solid phase peptide synthesis (SPPS) requiring large amounts of hazardous/toxic reagents and solvents which have negative environmental impacts. A possible solution is to develop a sustainable hybrid production platform incorporating recombinant production of cyclic peptide precursors in yeast followed by enzymatic maturation of these precursors into cyclic peptides using asparaginyl endopeptidases in vitro. Harnessing the efficient secretory pathway of Pichia pastoris, peptide precursors, cloned downstream of the α-mating factor secretion signal, were purified from culture supernatant mitigating the need for complex purification. To demonstrate the broad utility of the platform, three distinct classes of cyclic peptides were produced; two were structurally validated by NMR and shown to be functionally equivalent to their synthetically produced versions. Furthermore, using this platform we report the first recombinant production of any α-conotoxin in its native “globular” conformation. Using scale-up production in bioreactors, cyclic peptide yields of 85–97 mg L−1 of culture were achieved, far exceeding the highest yields so far achieved for cyclic disulfide-rich peptides in any recombinant process. This platform can potentially unlock production and facilitate applications of cyclic disulfide-rich peptides previously inaccessible through large-scale chemical synthesis and reduce their environmental burden.
- 15 October 2019
- Published by Springer Nature
- Vol. 2073, 17-37
Protein Expression in the Baculovirus-Insect Cell Expression System
The baculovirus-insect cell expression system is a popular choice for recombinant protein production. Post-translational modifications, production of protein complexes, and reported high protein yields are some of the favorable features of this eukaryotic expression system. The intricacies of the baculovirus-insect cell expression system may deter beginners from implementing it for routine protein production. This chapter documents a detailed protocol for using the baculovirus-insect cell expression system, which has been verified in a protein production research facility.
- 15 October 2019
- Published by Springer Nature
- Vol. 2073, 17-37
Protein Expression in the Baculovirus-Insect Cell Expression System
The baculovirus-insect cell expression system is a popular choice for recombinant protein production. Post-translational modifications, production of protein complexes, and reported high protein yields are some of the favorable features of this eukaryotic expression system. The intricacies of the baculovirus-insect cell expression system may deter beginners from implementing it for routine protein production. This chapter documents a detailed protocol for using the baculovirus-insect cell expression system, which has been verified in a protein production research facility.
- Open Access
- 31 December 2018
- Published by Wiley in Biotechnology and Bioengineering
- Vol. 116 (4) , 919-935
Synthetic biology for bioengineering virus‐like particle vaccines
Vaccination is the most effective method of disease prevention and control. Many viruses and bacteria that once caused catastrophic pandemics (e.g., smallpox, poliomyelitis, measles, and diphtheria) are either eradicated or effectively controlled through routine vaccination programs. Nonetheless, vaccine manufacturing remains incredibly challenging. Viruses exhibiting high antigenic diversity and high mutation rates cannot be fairly contested using traditional vaccine production methods and complexities surrounding the manufacturing processes, which impose significant limitations. Virus‐like particles (VLPs) are recombinantly produced viral structures that exhibit immunoprotective traits of native viruses but are noninfectious. Several VLPs that compositionally match a given natural virus have been developed and licensed as vaccines. Expansively, a plethora of studies now confirms that VLPs can be designed to safely present heterologous antigens from a variety of pathogens unrelated to the chosen carrier VLPs. Owing to this design versatility, VLPs offer technological opportunities to modernize vaccine supply and disease response through rational bioengineering. These opportunities are greatly enhanced with the application of synthetic biology, the redesign and construction of novel biological entities. This review outlines how synthetic biology is currently applied to engineer VLP functions and manufacturing process. Current and developing technologies for the identification of novel target‐specific antigens and their usefulness for rational engineering of VLP functions (e.g., presentation of structurally diverse antigens, enhanced antigen immunogenicity, and improved vaccine stability) are described. When applied to manufacturing processes, synthetic biology approaches can also overcome specific challenges in VLP vaccine production. Finally, we address several challenges and benefits associated with the translation of VLP vaccine development into the industry.
- 31 December 2018
- Published by Wiley in Biotechnology and Bioengineering
- Vol. 116 (4) , 919-935
Open AccessSynthetic biology for bioengineering virus‐like particle vaccines
Vaccination is the most effective method of disease prevention and control. Many viruses and bacteria that once caused catastrophic pandemics (e.g., smallpox, poliomyelitis, measles, and diphtheria) are either eradicated or effectively controlled through routine vaccination programs. Nonetheless, vaccine manufacturing remains incredibly challenging. Viruses exhibiting high antigenic diversity and high mutation rates cannot be fairly contested using traditional vaccine production methods and complexities surrounding the manufacturing processes, which impose significant limitations. Virus‐like particles (VLPs) are recombinantly produced viral structures that exhibit immunoprotective traits of native viruses but are noninfectious. Several VLPs that compositionally match a given natural virus have been developed and licensed as vaccines. Expansively, a plethora of studies now confirms that VLPs can be designed to safely present heterologous antigens from a variety of pathogens unrelated to the chosen carrier VLPs. Owing to this design versatility, VLPs offer technological opportunities to modernize vaccine supply and disease response through rational bioengineering. These opportunities are greatly enhanced with the application of synthetic biology, the redesign and construction of novel biological entities. This review outlines how synthetic biology is currently applied to engineer VLP functions and manufacturing process. Current and developing technologies for the identification of novel target‐specific antigens and their usefulness for rational engineering of VLP functions (e.g., presentation of structurally diverse antigens, enhanced antigen immunogenicity, and improved vaccine stability) are described. When applied to manufacturing processes, synthetic biology approaches can also overcome specific challenges in VLP vaccine production. Finally, we address several challenges and benefits associated with the translation of VLP vaccine development into the industry.
- 6 August 2018
- Published by Wiley in Biotechnology and Bioengineering
- Vol. 115 (12) , 2893-2907
Progression of continuous downstream processing of monoclonal antibodies: Current trends and challenges
Rapid advances in intensifying upstream processes for biologics production have left downstream processing as a bottleneck in the manufacturing scheme. Biomanufacturers are pursuing continuous downstream process development to increase efficiency and flexibility, reduce footprint and cost of goods, and improve product consistency and quality. Even after successful laboratory trials, the implementation of a continuous process at manufacturing scale is not easy to achieve. This paper reviews specific challenges in converting each downstream unit operation to a continuous mode. Key elements of developing practical strategies for overcoming these challenges are detailed. These include equipment valve complexity, favorable column aspect ratio, protein‐A resin selection, quantitative assessment of chromatogram peak size and shape, holistic process characterization approach, and a customized process economic evaluation. Overall, this study provides a comprehensive review of current trends and the path forward for implementing continuous downstream processing at the manufacturing scale.
- 6 August 2018
- Published by Wiley in Biotechnology and Bioengineering
- Vol. 115 (12) , 2893-2907
Progression of continuous downstream processing of monoclonal antibodies: Current trends and challenges
Rapid advances in intensifying upstream processes for biologics production have left downstream processing as a bottleneck in the manufacturing scheme. Biomanufacturers are pursuing continuous downstream process development to increase efficiency and flexibility, reduce footprint and cost of goods, and improve product consistency and quality. Even after successful laboratory trials, the implementation of a continuous process at manufacturing scale is not easy to achieve. This paper reviews specific challenges in converting each downstream unit operation to a continuous mode. Key elements of developing practical strategies for overcoming these challenges are detailed. These include equipment valve complexity, favorable column aspect ratio, protein‐A resin selection, quantitative assessment of chromatogram peak size and shape, holistic process characterization approach, and a customized process economic evaluation. Overall, this study provides a comprehensive review of current trends and the path forward for implementing continuous downstream processing at the manufacturing scale.